The Role of Topical Immune Response Modifiers in Skin Cancer
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 66 (13) , 1657-1664
- https://doi.org/10.2165/00003495-200666130-00001
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% CreamDermatologic Surgery, 2006
- Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor AgonistsDermatologic Surgery, 2004
- Death Receptor-Independent Apoptosis in Malignant Melanoma Induced by the Small-Molecule Immune Response Modifier ImiquimodJournal of Investigative Dermatology, 2004
- Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trialsJournal of the American Academy of Dermatology, 2004
- Randomized, Single-Blind, Placebo-Controlled Studyof Topical Application of the Immune Response ModulatorResiquimod in HealthyAdultsAntimicrobial Agents and Chemotherapy, 2003
- Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier ImiquimodJNCI Journal of the National Cancer Institute, 2003
- Successful topical immunotherapy of bowenoid papulosis with imiquimod.British Journal of Dermatology, 2001
- Imiquimod 5% cream in the treatment of Bowen's diseaseJournal of the American Academy of Dermatology, 2001
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Nonmelanoma Cancers of the SkinNew England Journal of Medicine, 1992